Tower Research Capital LLC (Trc) Inhibikase Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.54 - $0.91 $1,360 - $2,292	2,519 Added 23.29%	13,333 $9,000
Q4 2022 Feb 10, 2023	BUY	$0.45 - $0.78 $2,091 - $3,625	4,648 Added 75.38%	10,814 $5,000
Q3 2022 Nov 10, 2022	SELL	$0.76 - $1.11 $7,490 - $10,940	-9,856 Reduced 61.52%	6,166 $6,000
Q2 2022 Aug 15, 2022	BUY	$0.63 - $1.44 $9,087 - $20,772	14,425 Added 903.26%	16,022 $12,000
Q1 2022 May 12, 2022	SELL	$1.03 - $1.77 $4,947 - $8,501	-4,803 Reduced 75.05%	1,597 $2,000

Q4 2021 Feb 14, 2022	BUY	$1.38 - $2.17 $1,371 - $2,156	994 Added 18.39%	6,400 $10,000
Q3 2021 Nov 15, 2021	BUY	$1.79 - $2.81 $9,676 - $15,190	5,406 New	5,406 $10,000
Q2 2021 Aug 16, 2021	SELL	$2.8 - $6.23 $1,520 - $3,382	-543 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.2 - $7.95 $2,823 - $4,316	543 New	543 $3,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $33.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.